{"id":"oh2-injection","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"1-5%","effect":"Pneumonitis"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, OH2 injection blocks the interaction between PD-1 and its ligands, leading to the activation of T cells and an anti-tumor immune response.","oneSentence":"OH2 injection is a monoclonal antibody that targets the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:33.053Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07382531","phase":"PHASE1, PHASE2","title":"OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2023-09-07","conditions":"Solid Tumor","enrollment":30},{"nctId":"NCT05248789","phase":"PHASE2","title":"OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer","status":"TERMINATED","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2022-05-25","conditions":"Advanced Bladder Carcinoma","enrollment":4},{"nctId":"NCT04386967","phase":"PHASE1, PHASE2","title":"OH2 Injection in Solid Tumors","status":"RECRUITING","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2018-11-22","conditions":"Solid Tumor, Melanoma","enrollment":30},{"nctId":"NCT05235074","phase":"PHASE1, PHASE2","title":"OH2 Oncolytic Viral Therapy in Central Nervous System Tumors","status":"RECRUITING","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2021-11-16","conditions":"Central Nervous System Tumors","enrollment":28},{"nctId":"NCT05868707","phase":"PHASE3","title":"OH2 Injection in Melanoma","status":"RECRUITING","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2023-03-08","conditions":"Melanoma","enrollment":340},{"nctId":"NCT04616443","phase":"PHASE1, PHASE2","title":"OH2 Injection in Combination With HX008 for Melanoma.","status":"RECRUITING","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2020-12-01","conditions":"Melanoma","enrollment":60},{"nctId":"NCT05954091","phase":"PHASE1","title":"OH2 Administered by Intratumoral Injection","status":"NOT_YET_RECRUITING","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2025-09-01","conditions":"Solid Tumor","enrollment":29},{"nctId":"NCT05698459","phase":"PHASE1","title":"OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer","status":"RECRUITING","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2023-05-05","conditions":"Advanced Liver Cancer","enrollment":12},{"nctId":"NCT03866525","phase":"PHASE1, PHASE2","title":"OH2 Oncolytic Viral Therapy in Solid Tumors","status":"RECRUITING","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2019-04-02","conditions":"Solid Tumor, Gastrointestinal Cancer","enrollment":300},{"nctId":"NCT05232136","phase":"PHASE1, PHASE2","title":"OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2022-07-11","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":30},{"nctId":"NCT05648006","phase":"PHASE2","title":"First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer","status":"TERMINATED","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2023-10-17","conditions":"Advanced Colorectal Carcinoma","enrollment":7},{"nctId":"NCT04637698","phase":"PHASE1, PHASE2","title":"OH2 Oncolytic Viral Therapy in Pancreatic Cancer","status":"TERMINATED","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2021-02-02","conditions":"Pancreatic Cancer","enrollment":5},{"nctId":"NCT05070221","phase":"PHASE1","title":"Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2021-10-01","conditions":"Melanoma Stage IV","enrollment":30},{"nctId":"NCT05068453","phase":"PHASE1","title":"Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2021-10-01","conditions":"Melanoma Stage IV","enrollment":15},{"nctId":"NCT04755543","phase":"PHASE1","title":"A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms","status":"UNKNOWN","sponsor":"Taizhou HoudeAoke Biomedical Co., Ltd.","startDate":"2019-06-17","conditions":"Digestive System Neoplasms","enrollment":94},{"nctId":"NCT04100226","phase":"NA","title":"Vitamin D Deficiency and Effect of Its Supplementation on Interstitial Lung Diseases(ILD).","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2019-03-01","conditions":"Lung Diseases, Interstitial, Vitamin D Deficiency","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BS001"],"phase":"phase_3","status":"active","brandName":"OH2 injection","genericName":"OH2 injection","companyName":"Binhui Biopharmaceutical Co., Ltd.","companyId":"binhui-biopharmaceutical-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"OH2 injection is a monoclonal antibody that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}